SLC7A11 and lung cancer: The above results indicate that MA alleviates the resistance of lung cancer cells to osimertinib, mainly by inhibiting the KRAS-ERK pathway, as well as the KRAS-NRF2-SLC7A11 and FTH1 ferroptosis axis.